Background. Translocation-associated renal cell carcinoma involving ALK (ALK-tRCC) is a rare subtype of adult renal cell carcinoma (RCC) reported in recent years. Case presentation. A new Italian case of ALK-tRCC was reported. The patient was a female 44-year-old with a metastatic and pretreated RCC. The tumor showed a rearrangement of ALK gene in tumor cells detected by targeted next-generation sequencing panel. The patient received oral alectinib therapy and achieved a partial response. Conclusions. ALK-tRCC is a rare subtype of adult RCC. Its diagnosis is very difficult because the genomic alteration spectrum is very wide. We suggested that metastatic RCCs should be screened for uncommon genomic alterations ex-pecially in good performance status pretreated resistant/ refractory patients.

Identification of anaplastic lymphoma kinase fusion in clear cell renal carcinoma (ALK-tRCC): a precision oncology medicine case report / Varchetta, V.; Campanella, C.; Rossi, M.; Verzaro, R.; Vitale, M.; Soda, G.; Mancuso, A.. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 0034-1193. - 112:1(2021), pp. 14-15. [10.1701/3525.35133]

Identification of anaplastic lymphoma kinase fusion in clear cell renal carcinoma (ALK-tRCC): a precision oncology medicine case report

Verzaro R.;Soda G.
Penultimo
;
2021

Abstract

Background. Translocation-associated renal cell carcinoma involving ALK (ALK-tRCC) is a rare subtype of adult renal cell carcinoma (RCC) reported in recent years. Case presentation. A new Italian case of ALK-tRCC was reported. The patient was a female 44-year-old with a metastatic and pretreated RCC. The tumor showed a rearrangement of ALK gene in tumor cells detected by targeted next-generation sequencing panel. The patient received oral alectinib therapy and achieved a partial response. Conclusions. ALK-tRCC is a rare subtype of adult RCC. Its diagnosis is very difficult because the genomic alteration spectrum is very wide. We suggested that metastatic RCCs should be screened for uncommon genomic alterations ex-pecially in good performance status pretreated resistant/ refractory patients.
2021
alectinib; ALK fusion; molecular biology; NGS panel; precision oncology; renal cancer; target therapy
01 Pubblicazione su rivista::01i Case report
Identification of anaplastic lymphoma kinase fusion in clear cell renal carcinoma (ALK-tRCC): a precision oncology medicine case report / Varchetta, V.; Campanella, C.; Rossi, M.; Verzaro, R.; Vitale, M.; Soda, G.; Mancuso, A.. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 0034-1193. - 112:1(2021), pp. 14-15. [10.1701/3525.35133]
File allegati a questo prodotto
File Dimensione Formato  
Varchetta_Identification of anaplastic_2021.pdf

accesso aperto

Note: https://www.recentiprogressi.it/archivio/3525/articoli/35133/
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 66.81 kB
Formato Adobe PDF
66.81 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1560319
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? ND
social impact